Doxorubicin, bleomycin, vinblastine and dacarbazine chemotherapy with interferon for advanced stage classic Hodgkin lymphoma: a 10-year follow-up study

References

• Jemal A, Siegel R, Ward E, . Cancer statistics, 2009. CA Cancer J Clin 2009;59:225–249.
   PubMed Web of Science ®Google Scholar
• Jemal A, Siegel R, Xu J, . Cancer statistics, 2010. CA Cancer J Clin 2010;60:277–300.
   PubMed Web of Science ®Google Scholar
• Surveillance Epidemiology and End Results. SEER Stat Fact Sheets: Hodgkin lymphoma. Available from: http://seer.cancer.gov/statfacts/html/hodg.html.
   Google Scholar
• Horning S, Fanale M, deVos S, . Defining a population of Hodgkin lymphoma patients for novel therapeutics: an international effort. Ann Oncol 2008;19(Suppl. 4): Abstract 118.
   Google Scholar
• Haluska FG, Brufsky AM, Canellos GP, . The cellular biology of the Reed-Sternberg cell. Blood 1994;84:1005–1019.
   PubMed Web of Science ®Google Scholar
• Smith CA, Farrah T, Goodwin G. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 1994;76:959–962.
   PubMed Web of Science ®Google Scholar
• Smith CA, Gruss HJ, Davis T, . CD30 antigen, a marker for Hodgkin's lymphoma, is a receptor whose ligand defines an emerging family of cytokines with homology to TNF. Cell 1993;73: 1349–1360.
   PubMed Web of Science ®Google Scholar
• Urba WJ, Longo DL. Hodgkin's disease. N Engl J Med 1992;326: 678–687.
   PubMed Web of Science ®Google Scholar
• Hasenclever D, Diehl V. A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. N Engl J Med 1998;339:1506–1514.
   PubMed Web of Science ®Google Scholar
• Duggan DB, Petroni GR, Johnson JL, . Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 2003;21:607–614.
   PubMed Web of Science ®Google Scholar
• Horning SJ, Merigan TC, Krown SE, . Human interferon alpha in malignant lymphoma and Hodgkin's disease. Results of the American Cancer Society trial. Cancer 1985;56:1305–1310.
   PubMed Web of Science ®Google Scholar
• Solal-Celigny P, Lepage E, Brousse N, . Recombinant interferonalfa-2b combined with a regimen containing doxorubicin in patients with advanced follicular lymphoma. N Engl J Med 1993; 329:1608–1614.
   PubMed Web of Science ®Google Scholar
• Wedgwood A, Fanale M, Fayad L, . Rituximab + ABVD improves event-free survival (EFS) in patients with classical Hodgkin lymphoma in all International Prognostic Score (IPS) groups and in patients who have PET positive disease after 2–3 cycles of therapy. Blood 2007;110(Suppl. 1): Abstract 215.
   Google Scholar
• Jaffe ES, Harris NL, Stein H, editors. World Health Organization classification of tumours – pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, France: International Agency for Research on Cancer; 2001.
   Google Scholar
• Lister TA, Crowther D, Sutcliffe SB, . Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989;7:1630–1636.
   PubMed Web of Science ®Google Scholar
• Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood 2002;99:4283–4297.
   PubMed Web of Science ®Google Scholar
• Cheson BD, Pfistner B, Juweid ME, . Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25:579–586.
   PubMed Web of Science ®Google Scholar
• Mazza P, Tura S, Bocchia M, . Alpha-2b recombinant interferon (Intron) in Hodgkin's lymphoma: therapeutic perspective. Eur J Haematol Suppl 1990;52:22–24.
   PubMedGoogle Scholar
• Takeyama H, Yano K, Fukutani H, . A preliminary study of chemo-interferon therapy in malignant lymphoma. Gan To Kagaku Ryoho 1987;14:140–145.
   PubMedGoogle Scholar
• Coiffier B, Neidhardt-Bérard EM, Tilly H, . Fludarabine alone compared to CHVP plus interferon in elderly patients with follicular lymphoma and adverse prognostic parameters: a GELA study. Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol 1999;10:1191–1197.
   PubMed Web of Science ®Google Scholar
• Renault F, Hoofnagle JH, Park Y, . Psychiatric complications of long-term interferon alfa therapy. Arch Intern Med 1987;147:1577–1580.
   PubMed Web of Science ®Google Scholar
• Copeland A, Cao Y, Fanale M, . Final report of a phase II study of rituximab plus ABVD for patients with newly diagnosed advanced stage classical Hodgkin lymphoma: results of long follow-up and comparison to institutional historical data. Blood 2009;114(Suppl. 1): Abstract 1680.
   Google Scholar
• Younes A, McLaughlin P, Fayad L, . Six weekly doses of rituximab plus ABVD for newly diagnosed patients with advanced stage classical Hodgkin lymphoma: depletion of reactive B-cells from the microenvironment by rituximab. Blood 2005;106(Suppl. 1): Abstract 1499.
   Google Scholar
• Younes A, Fayad L, Goy A, . Results of rituximab plus ABVD in 65 newly diagnosed patients with classical Hodgkin lymphoma: improvement of event-free survival (EFS) in all International Prognostic Score (IPS) groups. Blood 2006;108(Suppl. 1): Abstract 2742.
   Google Scholar
• Engert A, Plütschow A, Eich HT, . Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010;363:640–652.
   PubMed Web of Science ®Google Scholar
• Oki Y, Younes A. Does rituximab have a place in treating classic Hodgkin lymphoma? Curr Hematol Malig Rep 2010;5:135–139.
   PubMed Web of Science ®Google Scholar
• Yazbeck V, Georgakis GV, Wedgwood A, . Hodgkin's lymphoma: molecular targets and novel treatment strategies. Future Oncol 2006;2:533–551.
   PubMedGoogle Scholar